The early experiences with enfortumab vedotin in patients with metastatic bladder cancer

Enfortumab vedotin je inovativn clen lk pro lbu metastatickho ndoru moovho mche. Nsledujc lnek prezentuje svm prbhem dva odlin ppady spolu s nedoucmi inky indukovan touto lbou. Tyto dva ppady podtrhuj nutnost pelivho monitorovn a zen nedoucch ink. Nae zkuenosti poukazuj na potebu zajitn rovnovhy mezi efektivitou a bezpenost lby enfortumab vedotinem, kde i pes vysok terapeutick potencil mus bt pstup k lb individualizovn s ohledem na monou toxicitu.

Authors

Jindřich Kopecký (ORCID: https://orcid.org/0000-0002-4126-0410)

Publication Details

Journal: Onkologie
Published: 2024-10-02
DOI: https://doi.org/10.36290/xon.2024.045
Primary Topic: Bladder and Urothelial Cancer Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

The early experiences with enfortumab vedotin in patients with metastatic bladder cancer

Jindřich Kopecký

Oct 2, 2024

Onkologie

Bladder and Urothelial Cancer Treatments

article

The early experiences with enfortumab vedotin in patients with metastatic bladder cancer

Jindřich Kopecký

October 2, 2024article en

Abstract

OnkologieVol. 18(Suppl.C)

Openalex Percentile: Top 68%

Bladder and Urothelial Cancer Treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The early experiences with enfortumab vedotin in patients with metastatic bladder cancer — Jindřich Kopecký · Onkologie (2024) | TGRS Research Map | TGRS